Canine CYP1A2 genetic polymorphism

Details Canine CYP1A2 genetic polymorphism Canine CYP1A2 genetic polymorphism

2004-05-28

2008-07-15

Goldberg, Jeanine A (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C435S091200, C536S023100, C536S024300

Reexamination Certificate

active

07399587

ABSTRACT:
Disclosed is a method for determining whether a dog is an extensive metabolizer or a poor metabolizer in the rate of drug metabolism, by preparing a DNA sample from a dog, and determining a base corresponding to a base at position 1117 of a canine CYP1A2 gene (i.e., at position 87 of exon 4). According to the method, a CYP1A2 gene diagnosis of dogs (particularly beagles) used in a pharmacological effect test or a toxicity test can be rapidly carried out prior to the test, and thus the dogs can be easily divided into a group having a normal metabolic ability (an extensive metabolizer group) and a group having a low metabolic ability (a poor metabolizer group).

REFERENCES:
patent: 0 873 998 (1998-10-01), None
patent: WO 96/16172 (1996-05-01), None
Mise (Pharmacogenetics, vol. 14, pp. 769-773, Nov. 2004).
Tacher et al. (J. of Heredity, vol. 96, No. 7, pp. 812-816, 2005).
Uchida et al. (Molecular Pharmacology, vol. 38, pp. 644-651, 1990).
Translation of International Preliminary Report on Patentability, for PCT Application No. PCT/JP2004/007356, filed May 28, 2004.
Supplementary Partial European Search Report dated Aug. 16, 2006, for EP Application No. 04745392.3.
Azuma et al., “Comparative Analysis of In Vitro and In Vivo Pharmacokinetic Parameters Related to Individual Variability of GTS-21 in Canine,” Drug Metabol. Pharmacokin., 17(1): 75-82 (2002).
Mise et al., “Polymorphic Expression of CYP1A2 Leading to Interindividual Variability in Metabolism of a Novel Benzodiazepine Receptor Partial Inverse Agonist in Dogs,” Drug Metabolism and Disposition, 32:240-245 (2004).
Mise et al., “Identification of Non-functional Allelic Variant ofCYP1A2in Dogs,” Pharmacogenetics, 14:769-773 (2004).
Tenmizu et al., “Identification of the Novel Canine CYP1A2 1117 C>T SNP Causing Protein Deletion,” Xenobiotica, 34(9): 835-846 (2004).
Nagata et al., “Genetic Polymorphism of Human Cytochrome P450 Involved in Drug Metabolism,”Drug Metabol. Pharmacokin., 17(3):167-189 (2002).
Uchida et al, “Isolation of cDNAs Coding for Three Different Forms of Liver Microsomal Cytochrome P-450 from Polychlorinated Biphenyl-Treated Beagle Dogs,”Molecular Pharmacology, 38:644-651 (1990).
Office Action dated Nov. 30, 2007, in Canadian Application No. 2,511,404 for “Canine CYP1A2 Gene Polymorphism.”

Affiliated with

Also associated with

Rating

Canine CYP1A2 genetic polymorphism does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Canine CYP1A2 genetic polymorphism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Canine CYP1A2 genetic polymorphism will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3963500